Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biogen Hemophilia Spin Out Bioverativ On Track For Early 2017

Executive Summary

Bioverativ was unveiled as the name for Biogen’s spin out; an initial Form 10 registration will be filed with SEC later this week.


Related Content

Stockwatch: Mistaken Acquisitions Dim Earnings Season
Bioverativ Hits The Street Ready To Expand In Blood Disorders
Sobi Seeks New CEO Who Is Around Sweden, Europe As Business Grows
Hemophilia And Rare Diseases Drive European Mid-Pharmas Sobi And Recordati
Biopharma Quarterly Dealmaking Statistics, Q2 2016
Alnylam's Fitusiran Could Provide Comprehensive Hemophilia Therapy Option
Start-Up Quarterly Statistics, Q2 2016
Biogen Backs Out Of Hemophilia, But Who Benefits?


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts